Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularization
- 29 November 2008
- journal article
- retinal disorders
- Published by Springer Nature in Albrecht von Graefes Archiv für Ophthalmologie
- Vol. 247 (3), 311-318
- https://doi.org/10.1007/s00417-008-0995-0
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Marginal crack after intravitreal bevacizumab for myopic choroidal neovascularizationActa Ophthalmologica, 2009
- Treatment of Exudative Age-related Macular Degeneration: Many Factors to ConsiderAmerican Journal of Ophthalmology, 2007
- Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot studyBritish Journal of Ophthalmology, 2007
- Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot studyBritish Journal of Ophthalmology, 2007
- Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continuesBritish Journal of Ophthalmology, 2007
- Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopiaBritish Journal of Ophthalmology, 2007
- Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopiaBritish Journal of Ophthalmology, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular DegenerationNew England Journal of Medicine, 2006
- Novel mechanism for age‐related macular degeneration: An equilibrium shift between the angiogenesis factors VEGF and PEDFJournal of Cellular Physiology, 2001